A unique life-saving smart-watch for high quality, not-invasive, continuous blood pressure monitoring.

Fact Sheet

Project Information

BP24

Grant agreement ID: 781861

Project website

DOI
10.3030/781861

Project closed

EC signature date
10 July 2017

Start date
1 August 2017

End date
31 December 2017

Funded under
INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Total cost
€ 71 429,00

EU contribution
€ 50 000,00

Coordinated by
VITA-SENTRY LTD
Israel

Objective

Human body tries to keep blood pressure as stable and constant as possible, so its instabilities are indicators of systemic
problems. Among 1 B people affected by hypertension, however, blood pressure monitoring is ineffective at least in 47% of
them, leading to 9 M deaths/year globally. Current monitors for self blood pressure monitoring show main drawbacks: they

interfere with daily activities, often lack of reliability and standards, and only allow to measure the blood pressure
intermittently, so information on the blood pressure trend is not available. BP24 is a wearable medical device for
noninvasive, continuous and highly accurate blood pressure monitoring, specifically targeting patients with hypertension and
inpatients. Vita Sentry's proprietary core technology enables a unique approach that takes into account the vascular tone to
compute the value of BP, instead of simply estimating it from the measure of the blood flow. By detecting the diameter of
arteries and arterioles with an accuracy of 0.5 µm over a measurement range, BP24 is the unique wearable intended for
highly accurate -golden-standard comparable- BP monitoring. Therefore, not only it can be used by patients with
hypertension, but in the future it will be used in patients undergoing surgeries – and the company's efforts are directed
towards that objective. Vita Sentry's technology is enabling: being vasodilation and vasoconstriction in a number of
physiological processes, knowing the arteries and arteriole diameters will allow to measure the metabolic rate and the stress
level of a person. While this is a long-term objective, going to the market with BP24 for self-monitoring of people with
hypertension is the goal of the innovation project. During Phase 1 project the Company will assess the scale-up
industrialization plan, the trials needed to demonstrate the validity of the proposed solution and will evaluate a sound go-tomarket
strategy to ensure successful commercialization of the device.

Fields of science (EuroSciVoc)

medical and health sciences > health sciences > health care services > **eHealth**

natural sciences > computer and information sciences > internet > **internet of things**

medical and health sciences > clinical medicine > **surgery**

social sciences > economics and business > business and management > **business models**

medical and health sciences > clinical medicine > cardiology > **cardiovascular diseases**

Programme(s)

H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) MAIN PROGRAMME

H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Topic(s)

SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme

Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-1-2016-2017

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

VITA-SENTRY LTD

Net EU contribution

€ 50 000,00

Total cost

€ 71 429,00

Address

17 MOTZKIN STR.
4246017 NETANYA
Israel

SME

Yes

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Contact the organisation

Participation in EU R&I programmes

HORIZON collaboration network

Last update: 5 August 2022

Permalink: https://cordis.europa.eu/project/id/781861